Compare GRWG & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRWG | KRRO |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.2M | 105.0M |
| IPO Year | 2015 | 2019 |
| Metric | GRWG | KRRO |
|---|---|---|
| Price | $1.08 | $12.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $2.50 | ★ $47.10 |
| AVG Volume (30 Days) | ★ 280.2K | 150.7K |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $193,365,479.00 | $6,392,000.00 |
| Revenue This Year | N/A | $145.97 |
| Revenue Next Year | $4.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 142.51 | ★ 181.46 |
| 52 Week Low | $0.83 | $5.20 |
| 52 Week High | $2.40 | $55.89 |
| Indicator | GRWG | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 34.63 | 59.64 |
| Support Level | $1.06 | $12.17 |
| Resistance Level | $1.09 | $15.05 |
| Average True Range (ATR) | 0.05 | 0.89 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 5.00 | 54.61 |
GrowGeneration Corp owns and operates specialty retail hydroponic and organic gardening stores. The firm is a marketer and distributor of nutrients, growing media, indoor and greenhouse lighting, ventilation systems and accessories for hydroponic gardening. The Company has two reportable segments, including Cultivation and Gardening segment, composed of the Company's hydroponic and organic gardening business; and the Storage Solutions segment, composed of the Company's benching, racking, and storage solutions business.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.